Michael C. Jensen

CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

A. Wu, S. Forman, M. Jensen, 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Human T lymphocyte genetic modification with naked DNA.

M. Slovak, A. Wu, S. Forman, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

A. Wu, S. Forman, M. Jensen, 2003, Cytotherapy.